{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:05:19Z","timestamp":1791212719378,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,11]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>In 2017, the hepatitis C treatment regimens sofosbuvir\/velpatasvir\/voxilaprevir (SOF<\/jats:styled-content>\/VEL<\/jats:styled-content>\/VOX<\/jats:styled-content>) and glecaprevir\/pibrentasvir (G\/P) received approval from the U.S. Food and Drug Administration. Although both SOF<\/jats:styled-content>\/VEL<\/jats:styled-content>\/VOX<\/jats:styled-content> (NS<\/jats:styled-content>5B polymerase inhibitor\/NS<\/jats:styled-content>5A inhibitor\/NS<\/jats:styled-content>3\/4A protease inhibitor) and G\/P (NS<\/jats:styled-content>3\/4A protease inhibitor\/NS<\/jats:styled-content>5A inhibitor) are pangenotypic regimens, they are indicated for distinct subsets of patients with hepatitis C.<\/jats:p><\/jats:sec>Aim<\/jats:title>To compare and contrast available safety and efficacy data for SOF<\/jats:styled-content>\/VEL<\/jats:styled-content>\/VOX<\/jats:styled-content> and G\/P and outline their clinical utility.<\/jats:p><\/jats:sec>Methods<\/jats:title>For each of the regimens, this review outlines the indications, safety information, and the major clinical studies in which SOF<\/jats:styled-content>\/VEL<\/jats:styled-content>\/VOX<\/jats:styled-content> and G\/P were evaluated.<\/jats:p><\/jats:sec>Results<\/jats:title>SOF<\/jats:styled-content>\/VEL<\/jats:styled-content>\/VOX<\/jats:styled-content> is positioned as a salvage regimen for patients previously treated with NS<\/jats:styled-content>5A inhibitors and for genotype 1a\u2010 and 3\u2010infected patients who had failed other sofosbuvir\u2010containing regimens. G\/P is the first pangenotypic regimen with an 8\u2010week duration for treatment\u2010na\u00efve, non\u2010cirrhotic patients, and it is indicated for patients with any genotype who have advanced kidney disease, including those on dialysis.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The addition of SOF<\/jats:styled-content>\/VEL<\/jats:styled-content>\/VOX<\/jats:styled-content> and G\/P to existing hepatitis C treatment options will expand the number of patients who are eligible for and responsive to treatment, thus increasing the possibility of eliminating hepatitis C as a public health issue.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14977","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T04:00:25Z","timestamp":1538798425000},"page":"914-923","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Review article: novel antivirals for hepatitis C\u2014sofosbuvir\/velpatasvir\/voxilaprevir, glecaprevir\/pibrentasvir"],"prefix":"10.1111","volume":"48","author":[{"given":"Brian L.","family":"Pearlman","sequence":"first","affiliation":[{"name":"Center for Hepatitis C Wellstar Atlanta Medical Center Atlanta Georgia"},{"name":"The Medical College of Georgia Augusta Georgia"},{"name":"Emory School of Medicine Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Hinds","sequence":"additional","affiliation":[{"name":"Center for Hepatitis C Wellstar Atlanta Medical Center Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1297928"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S127689"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1351295"},{"key":"e_1_2_8_6_1","unstructured":"Gilead Sciences.VOSEVI: Highlights of Prescribing Information.http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/vosevi\/vosevi_pi.pdf. Accessed December 21 2017."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29601"},{"key":"e_1_2_8_8_1","unstructured":"AbbVie Inc.MAVYRET: Highlight of Prescribing Information.http:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf. Accessed December 21 2017."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29109"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13874"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"issue":"1","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/S0168-8278(17)30915-7","article-title":"No impact of RASs on the high efficacy of SOF\/VEL\/VOX for 12 weeks in DAA\u2010experienced patients: an integrated resistance analysis of the POLARIS\u20101 and POLARIS\u20104 studies","volume":"66","author":"Sarrazin C","journal-title":"J Hepatol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.047"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31102-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29541"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30467-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_8_24_1","unstructured":"U.S. Food & Drug Administration.FDA Approves Mavyret for Hepatitis C.https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm570038.htm. Accessed December 14 2017."},{"key":"e_1_2_8_25_1","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America.Recommendations for Testing Managing and Treating Hepatitis C.http:\/\/www.hcvguidelines.org\/. Accessed January 5 2018."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31399-5"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30427-6"},{"key":"e_1_2_8_28_1","unstructured":"Merck & Co.ZEPATIER Highlights of Prescribing Information.https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf. Accessed July 17 2017."},{"key":"e_1_2_8_29_1","unstructured":"Gilead Sciences.HARVONI Highlights of Prescribing Information.https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf. Accessed July 18 2107."},{"key":"e_1_2_8_30_1","unstructured":"Gilead Sciences.EPCLUSA Highlights of Prescribing Information.https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/epclusa\/epclusa_pi.pdf. Accessed May 11 2018."}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14977","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T21:31:25Z","timestamp":1694295085000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/apt.14977"],"URL":"https:\/\/doi.org\/10.1111\/apt.14977","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"2018-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}